Evidence map›Paper›PMID 41606226›Full record

SynthesisNaunyn-Schmiedeberg's archives of pharmacology2026

Methodological quality of network meta-analyses of Chinese herbal medicine could be improved: an evidence mapping.

Yang Liu, Guang Yi, Anna Dai, Yifan Liao, Siyu Liu, Maoyi Yang, Rensong Yue, Zhipeng Hu

Abstract readSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yang Liu *Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Guang Yi *Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Anna Dai *Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Yifan LiaoChengdu University of Traditional Chinese Medicine, Chengdu, China.
Siyu LiuChengdu University of Traditional Chinese Medicine, Chengdu, China.
Maoyi YangDepartment of Endocrinology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China. 3406673658@qq.com.
Rensong YueDepartment of Endocrinology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China. 1580229694@qq.com.
Zhipeng HuDepartment of Endocrinology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China. 545053309@qq.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Network meta-analyses (NMAs) are essential for comparing multiple Chinese herbal medicine (CHM) interventions, but their methodological rigor requires evaluation. We systematically searched five databases for CHM NMAs published from inception to June 2025. Studies were included if they were English-language, SCI/SSCI-indexed NMAs evaluating at least one pharmacopoeia-listed CHM. Conference abstracts, editorials, expert opinions, conference proceedings, case reports, and Meta-analyses were excluded. Two reviewers independently screened studies, extracted data, and appraised methodological quality using AMSTAR 2. Factors associated with quality (dichotomized as high/moderate vs. low/critically low) were examined using logistic regression. Of 1,016 identified records, 212 NMAs were included, encompassing 13,575 primary studies and 1,302,518 participants. Methodological quality was generally low: 1.42% were high, 5.19% moderate, 61.32% low, and 32.08% critically low. Common shortcomings involved literature search comprehensiveness, listing of excluded studies, reporting of funding sources for included trials, and assessment of risk of bias impact. In multivariable analysis, a larger number of authors (OR = 1.177, 95% CI: 1.014-1.366, p = 0.032) was associated with higher quality. An association was also observed for non-China corresponding author country (OR = 7.914, 95% CI: 1.360-46.065, p = 0.021), although the wide confidence interval warrants cautious interpretation. The assessment was based on AMSTAR 2, which is not NMA-specific. Restriction to SCI/SSCI journals may have excluded lower-quality studies. This work was supported by grants from the National Natural Science Foundation of China (82,305,209, 82,505,508) and other local funds. This systematic review was not preregistered. The methodological quality of published CHM NMAs is predominantly low. Enhancing team size and collaboration, alongside strict adherence to core methodological standards, is crucial for improving the reliability and utility of future evidence syntheses in this field.

Indexed as

Drugs, Chinese HerbalNetwork Meta-Analysis as TopicHumansResearch DesignDrugs, Chinese HerbalAMSTAR2Chinese Herbal MedicineMethodological qualityNetwork meta-analyses

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.